Revenue and net profit declined year-over-year, but net profit margins improved. The board approved the sale of the Nasense Labs stake, which contributed significantly to prior revenue and net worth. Rights issue proceeds were largely used for debt repayment.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.